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CancerExtracellular Hsp90 proteins, including “membrane-bound”, “released” and “secreted”, were ﬁrst reported more
than two decades ago. Only studies of the past 7 years have begun to reveal a picture for when, how and why
Hsp90 gets exported by both normal and tumor cells. Normal cells secrete Hsp90 in response to tissue injury.
Tumor cells have managed to constitutively secrete Hsp90 for tissue invasion. In either case, sufﬁcient supply of
the extracellular Hsp90 can be guaranteed by its unusually abundant storage inside the cells. Awell-characterized
function of secreted Hsp90α is to promote cell motility, a crucial event for both wound healing and cancer. The
reported targets for extracellular Hsp90α include MMP2, LRP-1, tyrosine kinase receptors and possibly more.
The pro-motility activity of secretedHsp90α resideswithin a fragment, called 'F-5', at the boundary between link-
er region andmiddle domain. Inhibition of its secretion, neutralization of its extracellular action or interruption of
its signaling through LRP-1 block wound healing and tumor invasion in vitro and in vivo. In normal tissue, topical
application of F-5 promotes acute anddiabeticwoundhealing farmore effectively thanUS FDA-approved conven-
tional growth factor therapy in mice. In cancer, drugs that selectively target the F-5 region of secreted Hsp90 by
cancer cells may be more effective and less toxic than those that target the ATPase of the intracellular Hsp90.
This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).hock Protein 90 (HSP90).
m-6320, Los Angeles, California
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Since the discovery of the ﬁrst “growth factor” in the 70s, it has
become widely believed that local growth factors are the driving
force for wound healing, i.e. the lateral migration and proliferation
of epidermal keratinocytes over the wound bed to close the wound
and the inward migration and growth of dermal ﬁbroblasts and mi-
crovascular endothelial cells into the wound bed to remodel the
damaged tissue and to build a new vascularized neodermis [1–3].
However, after two decades of extensive studies and clinical trials
on a handful of growth factors alone or in combination [3,4], only
recombinant human platelet-derived growth factor-BB (PDGF-BB)
has received US FDA approval for topical treatment of diabetic ul-
cers (Regranex/becaplermin gel, 0.01%, Ortho-McNeil Pharmaceuti-
cal, Raritan, NJ) [5–7]. Since then, however, its modest efﬁcacy,
high cost and risk of causing cancer in patients (who receive
three tubes or more of the treatment) have limited the use of
PDGF-BB in clinical practice [8,9]. While these rather unexpected out-
comes have clearly implicated that conventional growth factors are not
the critical force of wound closure as they were hoped for, this disap-
pointing reality has been continuously overlooked or simply ignored.
In 2007, Li and colleagues proposed that the factor that is primarilyresponsible for promoting the initial wound closure comes from secre-
tion of the stressed skin cells at the wound edge. From the secreted pro-
teins of primary human keratinocytes and human dermal ﬁbroblasts,
these authors found that secreted Hsp90α promotes wound closure in
mice far more strongly than the becaplermin gel [10–12]. Why is secret-
ed Hsp90α chosen? Is secreted Hsp90α, instead of growth factors, re-
sponsible for the initial wound closure? No one would have imagined
and believed this.
Going back a decade, Csermely and colleagues raised a question
“Why do we need constitutively so much of Hsp90 (in a cell)”?
They argued that the major cellular function of Hsp90 is not entirely
as an intracellular chaperone. Instead, it is due to some other unrec-
ognized functions that would require such a large amount of Hsp90
protein stored in the cell [13]. In the late 1970s, a number of laborato-
ries have repeatedly reported expression of Hsp90 on the cell surface,
either as a tumor antigen or a protein that assists antigen presentation
to antigen-presenting cell [13–15]. Then, secreted form of Hsp90 was
reported to cause activation of ERK1/2 in rat vascular smooth muscle
cells [16] and stimulation of growth in lymphoid cells [17]. However, re-
sults of these earlier studies on extracellular Hsp90were largely viewed
as experimental artifacts for good reasons (see later sections). Since
2004, new evidence has started to accumulate and begun to shed light
on the Csermely's prediction. These new studies argue that the purpose
for the steady-state storage of such a large amount of Hsp90 in cells by
Mother Nature is for normal cells to launch a rapid protective response
to environmental insults, including heat, hypoxia, UV, gamma-irradiation,
reactive oxygen species (ROS), injury-released growth factors [14]. Tumor
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and metastasis [15,18]. In this review, we provide an updated analysis
of extracellular Hsp90, focusing on its role in skinwoundhealing and can-
cer progression.We are not going to discuss the antigen-presenting role
of cell-released Hsp90, which has been well covered in recent reviews
[19,20].
2. Suggestions for nomenclature of extracellular Hsp90
Cell surface-bound, cell-released and cell-secreted Hsp90 can be
collectively referred as “extracellular Hsp90”. It has become clear
that there are fundamental distinctions between intracellular and
extracellular Hsp90. First, one works inside and the other outside the
cell. Second, one acts as a chaperone and the other as a pro-motility fac-
tor (and possibly more). Third, one depends upon its N-terminal
ATPase, the middle domain for client molecule binding and C-terminal
dimerization/co-factor binding domains for effectiveness, whereas the
other uses a short peptide epitope at the boundary between the highly
charged linker region (LR) and themiddle domain (M) for promotion of
cell motility. Therefore, it has become necessary to distinguish these two
pools of Hsp90 by nomenclature. There have been several intuitive us-
ages of nomenclatures, including “surface-bound”, “released”, “secreted”
and “extracellular”. Among them, only the last nomenclature can include
both “cell surface-bound”, “released” and “secreted”Hsp90. Extracellular
Hsp90 was referred as “eHsp90” [21], similar to the nomenclature of
eDNA (extracellular DNA). Learning from other nomenclatures that in-
clude the word ‘extracellular’, such as extracellular matrix (ECM) and
extracellular ﬂuid (ECF), would extracellular Hsp90 go for “EC-
Hsp90”? These are suggestions for discussion. For the time being, we
use “eHsp90” throughout this article.
3. How much Hsp90 does a normal vs. a cancer cell have?
Hsp90 is widely reported as one of the most abundant proteins
in all types of cells, frequently being referred as “1–2% of the total
cellular proteins”. Three original reports, which were repeatedly
cited for this statement before the 90s, included a published ab-
stract and two research articles [22–24]. However, none of these
publications contained any direct supporting data for that state-
ment or even made that statement. Since then, a number of studies
actually tried to quantitate the content of Hsp90 protein either in
mouse or human issues [25–27] or in various normal or cancer cell
lines [28–31]. Some of these studies indeed provided numbers for
howmuch Hsp90 was found in their experiments. However, regardless
the accuracy of those reported numbers, none of these studies followed
theminimum requirements of the principles for protein quantitation in
biochemistry. At the least, the following steps should have been includ-
ed for estimation of a protein amount: 1) using a series of known
amounts of a protein standard (such as bovine serum albumin, MW
~55 kDa) to establish a standard curve of O.D. readings versus the actual
amounts (μg) of the protein; 2) serious titrationsof the total post-nuclear
extract of a given cell type, O.D. reading and conversion of the O.D. read-
ings into μg of proteins according to the Standard Curve; 3) subjecting
the cell extracts with known μg of proteins together with a series of
known μg of recombinant Hsp90α protein side-by-side to SDS-PAGE
and Western blot with a common monoclonal anti-Hsp90α antibody,
provided that the entire procedure of SDS-PAGE electrophoresis, transfer
onto nitrocellulose membranes, blotting, primary antibody, secondary
antibody, washing and ECL reactions of the two sets of samples are oper-
ated all in common apparatus, containers and the same exposure cas-
sette for the exactly same period of time; 4) subjecting Hsp90α protein
bands of the cell lysates and the recombinant Hsp90α to densitometry
scanning with identical settings of parameters (i.e. in Alpha Innotech
Fluorchem SP); 5) using the scanning readings of the recombinant
Hsp90α bands to establish a second Standard Curve that measures den-
sitometry readings versus the actual amounts (μg) of the recombinantHsp90α protein; 6) Using this standard curve to convert the scanning
readings of the Hsp90α bands from the total cell extracts to actual
amount (μg) of proteins; 7) dividing the amount of Hsp90α (μg) in a
given volume of cell extract by the total proteins (μg) from the same ex-
tract ×100 to obtain the approximate % of Hsp90α in the total proteins of
the given cell type; and 8) taking the means of the % from the multiple
sets of the Hsp90α versus cell extract pairs as the ﬁnal estimated % of
Hsp90α for a given cell type.When Sahu et al. followed these procedures
to compare multiple normal and cancer cell lines, they found that
Hsp90α protein accounts for 2–3% of the total cellular proteins in the
normal cells tested and up to 7% in certain tumor cell lines. However,
they also found that it was not always true that cancer cells have higher
levels of Hsp90 than its normal counterparts [32]. These numbers would
translate up to several hundred folds of Hsp90α proteins over other cel-
lular proteins in both normal and cancer cells, and these ratios could be-
come even larger if the copy number of Hsp90 is compared to any of its
chaperoned clients, which are often in much lower abundance than
other house keeping gene products.
4. eHsp90, secreted by living cells or leaked by dead cells?
Although the ﬁrst observation was made three decades ago, the
notion of “surface-bound” and “secreted” Hsp90 by living cells has
only recently gained traction in the ﬁeld with speciﬁc attributions of
a number of review articles by experts then and now [13–15,18].
Even though, skepticisms remain among many others as whether
these extracellular Hsp90 proteins are results of pathophysiological
processes or of a leak from a small number of dead cells in culture.
Multhoff and Hightower tried to address this critical issue 15 years
ago with a number of Hsp and non-Hsp examples in the studies
that used various pharmacological approaches and argued that
eHsp90 was no artifact [33].
The primary reason for this skepticism is that Hsp90 does not ﬁt
into any of the conventional categories of the actively secreted pro-
teins, such as growth factors, extracellular matrices (ECMs) and
matrix metaloproteinases (MMPs). First, Hsp90 has neither any sig-
nal peptide (SP) for secretion via the endoplasmic reticulum
(ER)/Golgi protein secretory pathway nor a recognizable trans-
membrane sequence for membrane anchoring. Second, there had al-
ready been reports that Hsp90 could be released to extracellular
environment following cell necrosis [14]. In the latter case, the released
Hsp90 binds and helps antigen recognition and triggers innate immune
responses. Therefore, it was arguable that eHsp90 found in conditioned
media of cultured cellsmay come froma small portion of dead cells [13].
Recent studies by independent groups have provided stronger argu-
ments that the cells secrete Hsp90 for purpose. First, quiescent normal
cells do not secrete Hsp90 [10,11,16]. However, many pathological
and stress cues trigger normal cells to secrete Hsp90, including reac-
tive oxygen species (ROS) [15], heat [34,35], hypoxia [10], gamma-
irradiation [36] and tissue injury-released cytokines, such as TGFα
[11]. For instance, TGFα is low or undetectable in intact skin and
only appears in thewound following skin injury. TGFα is known to in-
crease cell survival and cell number rather than causing cell death in
human keratinocytes. Interestingly, Cheng et al. showed that TGFα
stimulation causes rapid membrane translocation and secretion of
both endogenous and an exogenously expressed GFP-tagged Hsp90α
with defect in ATPase [11]. More speciﬁcally, Tsutsumi and colleagues
reported that a conserved hydrophobic motif in a beta-strand at the
boundary between the N-terminal domain and charged linker of
Hsp90 is required for Hsp90 secretion [37]. Wang et al. showed that a
C-terminal EEVDmotif and the Thr-90 phosphorylation both play a reg-
ulatory role inHsp90 secretion [38]. Onone hand, theseﬁndings strong-
ly support the notion that Hsp90 secretion is a regulated process. On the
other hand, it is hard to imagine why Hsp90 needs multiple distinct se-
quence motifs across the entire protein for regulation of its secretion,
not to mention how these motifs relate to the most reported exosome
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later section). More on regulation of Hsp90 secretion, Li and colleagues
identiﬁed a key upstream regulator of Hsp90α secretion, the hypoxia-in-
ducible factor-1alpha (HIF-1α) in human dermal ﬁbroblasts and kerati-
nocytes [10,39]. Dominant negative mutant of HIF-1α (DN-HIF-1α)
blocks the secretion, whereas a constitutively active mutant of HIF-1α
(CA-HIF-1α) makes the cells to secrete Hsp90α even under normoxia
[39]. The same mechanism appears to take place in tumor cells. Deple-
tion of the constitutively expressed HIF-1α or HIF-1β from breast can-
cer cells, MDA-MB-23, completely blocked the secretion of Hsp90α,
which could be rescued by exogenously re-introducing the CA-HIF-
1α, but not DN-HIF-1α [32]. Despite the above remarkable ﬁndings, di-
rect support for releasing Hsp90 on purpose by living cells would re-
quire additional studies on the detailed routes of its membrane
translocation and secretion in response to environmental cues.5. Induced secretion for normal cells and constitutive secretion for
tumor cells
Normal cells do not secrete Hsp90 unless being triggered by environ-
mental insults. Hightower and Guidon reported ﬁrst that heat-shocked
rat embryonic cells secrete Hsp90 and Hsp70. This secretion could not
be blocked bymonensin or colchicine, two inhibitors of the conventional
ER/Golgi protein secretory pathway [34]. Clayton and colleagues used
proteomic approach to analyze the peptide contents of B cell-secreted
proteins under either physiological temperature (37 °C) or heat shock
(44 °C for 3 h). They found that heat shock induced Hsp90α to go into
the nano-vesicles called exosomes and then secreted outside the cells
[35]. Liao et al. reported that treatment of rat vascular smooth muscle
cells with LY83583, an oxidative stress generator, caused secretion of
Hsp90α. The eHsp90α in turn induced a late phase activation of the
ERK1/2 pathway [16]. Yu and colleagues found that γ irradiation induced
secretion ofHsp90β, but notHsp90α, in a p53-dependent fashion via exo-
somes, proposing a “DNA damageNp53NHsp90β secretion” pathway
[34]. Cheng et al. showed that TGFα-induced Hsp90αmembrane translo-
cation and secretion to culture medium in primary human keratinocytes
were sensitive to inhibitors of the exosome protein trafﬁcking, but not
the conventional ER/Golgi protein trafﬁcking, pathway [11]. Finally, Li
and colleagues showed that hypoxia (1% O2) induced Hsp90α secretion
via HIF-1α. Blockade of eHsp90α function by neutralizing antibodies
completely inhibited hypoxia-induced cell motility [10].
In particular, the identiﬁcation of HIF-1α as a key upstream regulator
of Hsp90α secretion has an important implication in cancer. Hypoxia is a
known micro-environmental stress that is connected to the growth, in-
vasion, andmetastasis ofmany solid tumors [40]. Under constant hypox-
ia, cancer cells are forced to adapt, via HIF-1α, alternative and self-
supporting mechanisms for continued survival and expansion. Overex-
pression of HIF-1α has been estimated to occur in approximately 40%
of the tumors in humans [41]. Therefore, surface expression and/or secre-
tion of Hsp90α should become constitutive in those HIF-1α-
overexpressing tumors.While this prediction remains to be formally test-
ed, many tumor cell lines have been reported to secrete Hsp90. Kuroita
and colleagues reported puriﬁcation of Hsp90α from conditioned media
of human hybridoma SH-76 cells [17]. Eustace et al. reported Hsp90α,
but not Hsp90β, in conditioned media of HT-1080 tumor cells [42].
Wang et al. reported secretion of Hsp90α by MCF-7 human breast cells
[38]. Suzuki and Kulkarni found Hsp90β secreted byMG63 osteosarcoma
cells [45]. Chen and colleagues reported secretion of Hsp90α by colorectal
cancer cell line, HCT-8 [44].Work by Tsutsumi and colleagues implied se-
cretion of Hsp90α by a variety of tumor cell lines [43]. Finally, recent
study from our laboratory demonstrated that breast cancer cells,
MDA-MB-231 and MDA-MB-468, overexpress HIF-1α that causes con-
stitutive secretion of Hsp90α in a HIF-1-dependent fashion [32]. Fig. 1
summarizes what triggers Hsp90α secretion in normal cells versus
tumor cells, in which HIF-1α is a central regulator. However, thesignaling steps between HIF-1α and Hsp90α secretion machinery
(such as exosomes) remain entirely unknown.
6. Secretion of Hsp90α via non-classical exosomal protein secretory
pathway
How does Hsp90 travel through the cell membrane? There are
several cellular protein trafﬁcking machineries. First, the classical
ER/Golgi protein secretory pathway requires the to-be-secreted pro-
tein to have a 15–30 amino acid signal peptide (SP) at its amino ter-
minus and to use it as the “permit” for going out of the cell. The
second protein secretory pathway ismediated by secreted nano-vesicles,
called exosomes, which are used for secreting proteins that do not have
any SP sequences. Exosomes, also called ‘intraluminal vesicles’ (ILVs), are
non-plasma-membrane-derived vesicles that are 30–90 nm in diameter
and initially contained within the multivesicular bodies (MVB). A well-
known function ofMVB is to serve as an intermediate station during deg-
radation of the proteins internalized from the cell surface or sorted from
the trans Golgi organelle [46,47]. However, the MVB-derived exosomes
can also fuse with the plasma membrane to release their cargo proteins
into the extracellular space. This release process was reported to include
1) sorting into smaller vesicles; 2) fusing with the cell membrane; and
3) release of the vesicles to the extracellular space. All the proteins that
have been identiﬁed in exosomes are located in the cell cytosol or endo-
somal compartments, but never in the ER, Golgi apparatus, mitochondria
or nucleus. Making use of two chemical inhibitors, brefeldin A (BFA)
that selectively blocks the classical ER/Golgi protein secretory pathway
and dimethyl amiloride (DMA) that blocks the exosome protein secre-
tory pathway, several groups showed that DMA selectively inhibits
the membrane translocation and secretion of Hsp90α or Hsp90β by
various types of cells [11,48–51]. In the sameexperiments, BFAhad little
inhibition of Hsp90 secretion [11]. There have been no reports that BFA
or DMA causes more or less cell death. An unanswered question, how-
ever, is how stress signals, such as HIF-1α, are connected to this novel
protein secretory pathway and what are the relationships between
the reported secretion motifs in Hsp90 and exosomes. However, once
Hsp90α proteins are secreted outside the cells, they appear to be
“naked”, instead of continuing being wrapped in the exosomes, since
neutralizing anti-Hsp90α antibodies were able to completely block
their actions [10,11,32,39].
7. eHsp90 does not need ATPase for function
Eustace and colleagues studied the role of eHsp90α found in condi-
tioned media of HT-1080 ﬁbrosarcoma cells by using two approaches.
First, they used the ﬂuorophore-assisted light inactivation (FALI) tech-
nique, in which ﬂuorophore ﬂuorescein induces antibody-coupled FITC
to generate short-lived hydroxyl radicals that cause damage of proteins
within 40 Å. Therefore, the damage is often speciﬁc on the antibody-
bound protein, i.e. Hsp90α, but not surrounding proteins. This technique
damages the whole molecule. Second, they used DMAG-N-oxide, a gel-
danamycin/17-AAG-derived but cell-impermeable Hsp90 inhibitor that
targets the Hsp90's ATPase activity. They reported an importance of
eHsp90α in the tumor cell invasion [42]. Tsutsumi and colleagues also
tested the effect of DMAG-N-oxide on invasion of several cancer cell
lines in vitro and lung colonization by melanoma cells in mice and
reported inhibition of cell invasion in vitro and/or tumor formation in
vivo by DMAG-N-oxide [45]. The results of these studies suggested that
the N′-terminal ATP-binding and ATPase of Hsp90α are still required
for function of eHsp90α outside the cells. Focusing on the pro-motility
activity of eHsp90α on primary human skin cells, Cheng and colleagues
undertook mutagenesis approach to address the same issue. First, they
compared recombinant proteins of the wild type and E47A, E47D, and
D93N mutants of Hsp90α for pro-motility activity on human keratino-
cytes. As previously reported, Hsp90α-wt has a full ATPase activity,
Hsp90α-E47D mutant loses half of the ATPase activity, whereas
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Fig. 1. A schematic presentation of the “HypoxiaNHsp90α secretionNLRP-1NCell migration” signaling in normal vs. tumor cells. (A) In normal cells, secretion of Hsp90 does not
occur unless cells are “hit” with environmental stress cues, as listed. HIF-1α is a central regulator of Hsp90 secretion. Little is known about how HIF-1 “pushes” Hsp90 out of the
cell. The eHsp90 may act as an autocrine and paracrine factor to promote cell motility via LRP-1. The main duty for eHsp90 is to help tissue repair. (B) In many types of tumors,
HIF-1α is constitutively accumulated, which triggers secretion of Hsp90 even in the absence of any environmental stress cues. Tumor-secreted eHsp90α may promote tumor
cell migration via binding to LRP1 receptor, MMP2 and/or other targets. The tumor cells use eHsp90 mainly for tissue invasion. Therefore, eHsp90α and its extracellular targets
present new lines of targets for wound healing and anti-tumor drugs.
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[52]. Cheng et al. found that all the ATPase mutant proteins retained a
similar pro-motility activity as theHsp90α-wt. Second, theyused sequen-
tial deletion mutagenesis to have narrowed down the pro-motility do-
main to a region between the linker region (LR) and the middle (M)
domain of human Hsp90α [11]. Finally, their latest study has identiﬁed
a 115-amino acid fragment, called F-5 (aa-236 to aa-350), that promotes
skin cell migration in vitro andwound healing in vivo as effectively as the
full-length Hsp90α-wt [12]. Collectively, these ﬁndings demonstrate that
the N-terminal ATPase domain and the C-terminal dimer-forming and
co-factor-binding domain are dispensable for eHsp90α to promote cell
migration. A schematic representation of the structure and function re-
quirements for intracellular Hsp90α and eHsp90α is shown in Fig. 2A.
It should be pointed out that stimulation of cell migration might not be
the only function reported for eHsp90. The 115 amino acid sequence of
F-5 is highly conserved during evolution, as shown in Fig. 2B. However,
no more than 20% identity of F-5 was found in other Hsp family genes.
On the other hand, the observations made by Eustace, Tsutsumi and
their colleagues were independently conﬁrmed by studies of others.Cheng and colleagues in collaboration with Isaacs's group veriﬁed that
the DMAG-N-oxide inhibitor could indeed block the full-length
Hsp90α-stimulated human skin cell migration. However, as expected,
DMAG-N-oxide showed little inhibition of the F-5 peptide-induced
cell migration [Cheng, C-F, J. Isaacs andW. Li, unpublished] ormigration
induced by themiddle domain of eHsp90α [11,21].While the reason for
the apparent discrepancy remains unknown,we suggest that binding of
DMAG-N-oxide to the N′-terminal ATPase domain of the full-length
eHsp90α may cause a conformational change in eHsp90α, so that the
real functional epitope within eHsp90α, i.e. the F-5 region, becomes
cryptic. While this hypothesis remains to be tested, it can be concluded
that eHsp90 is no chaperone.
8. Downstream targets of eHsp90
How eHsp90α promotes cell migration has just begun to be appre-
ciated. Eustace and colleagues reported that Hsp90α, but not Hsp90β,
promotes cancer cell migration and invasion by binding and activating
the matrix metalloproteinase 2 (MMP2) [42]. Two independent groups
Extracellular Function (F-5) 
intracellular function intracellular function 
N’ domain LR M domain C’ domain 
1 235 272 629 732 
Fig. 2. A schematic distinction of the functional elements for intracellular vs. extracellular Hsp90β. (A) The intracellular chaperone function of Hsp90 requires almost the entire
molecule, especially the amino terminal (green) and the carboxyl terminal (blue) domains. The extracellular pro-motility function of Hsp90α depends on less than a 115 amino
acid fragment (F-5) located at the boundary between the LR and the M domains. This epitope appears at the surface of Hsp90 protein [ref. [13]]. (B) F-5 is highly conserved during
evolution of Hsp90 genes. Green, identify; Yellow: similarity; Red, distinction.
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[53,54,55] and, furthermore, showed that the M domain (aa-272 to
aa-617) of Hsp90α is responsible for the activation [53]. Following
their identiﬁcation of eHsp90α in conditioned media of human skin
cells in 2007 [10], Li and colleagues have also been attempting to iden-
tify a target that is essential for hypoxia- and eHsp90α-stimulated
human skin cell migration. First, they wanted to verify the involvement
of MMP2 or any other MMPs by utilizing two broad MMP inhibitors,
GM6001 (N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpenta-
noyl]-L-tryptophan methylamide, or Galardin) and MMP Inhibitor III
(hydroxamido-carbonylmethyl)-4-methylpentanoyl-L-tryptophan.
However, they found that presence of either GM6001 or MMP inhibitor
III showed little inhibitory effect on human recombinant Hsp90α-stim-
ulated human keratinocyte migration [11]. Whether this discrepancy is
due to differences in cellular contexts between the normal and the
tumor cells remains unclear. Besides MMP2, Sidera and colleagues
showed that a pool of cell membrane-bound Hsp90α interacts with the
HER-2 tyrosine kinase receptor in breast cancer cells, leading to increased
cell motility and invasion [54–56]. Suzuki and Kulkarni reported that
eHsp90β blocks the conversion from latent TGFβ to its active form, lead-
ing to decreased tumor suppressing effect of TGFβ [43]. McCready et al.
reported that eHsp90α exogenously delivered by addedexosomespartic-
ipated in plasminogen activation and tumor cell migration [57]. More-
over, Chung et al. showed that eHsp90 secreted by stressed vascular
SMCs regulates transcription of IL-8 gene [58]. While it is still distant
from understanding the mechanisms of action, these results at the least
suggest that eHsp90 has multiple downstream targets in distinct extra-
cellular environment.Among all the studies on eHsp90 targets since 2004, the investiga-
tion of LRP-1 as a cell surface receptor for eHsp90α has gone into rel-
atively more details and, therefore, is selected out here for
mentioning with a few extra sentences. Cheng et al. estimated that
eHsp90α could readily reach the optimal working concentrations of
0.05–0.1 μM that maximally stimulates cell migration in vitro [11].
In their cell migration assays, human recombinant Hsp90α exhibited
a saturating and subsequently declined effect on human skin cells,
when increasing amounts of eHsp90α were added. This was an im-
portant observation that suggests that eHsp90α acts by binding to a
receptor-like molecule on the cell surface with certain Km (50% of
equilibrium) and Kd (dissociation constant) values. Then, Cheng et
al. used four independent approaches (neutralizing antibodies, RAP
(LRP-1-associated protein) inhibitor, RNAi, and somatic LRP-1 mutant
cell line), to prove that the widely expressed cell surface receptor,
LRP-1, mediates the eHsp90α signaling to promote cell migration. In
vitro, GST-eHsp90 directly pulled down LRP-1 via its pro-motility
fragment between the LR and the M domain of Hsp90α [11]. More
convincingly, when these authors re-introduced an RNAi-resistant
mini-LRP-1 cDNA into the LRP1-downregulated cells, they were able
to rescue the migration response of the cells to either eHsp90α or
hypoxia. These ﬁndings led the investigators to propose the following
working model: “HypoxiaNHIF-1αNHsp90α secretionNLRP-1Ncell
motility” autocrine pathway for tissue repair and tumor invasion
and metastasis [37], as previously shown in Fig. 1.
However, it is equally important to point out the complexity of
LRP-1 receptor signaling. First, LRP-1 (also called CD91) is a large het-
erotrimeric protein consisting of a 515-kDa extracellular domain and
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found in monocytes, hepatocytes, ﬁbroblasts, and keratinocytes [60–
62]. Second, LRP-1 is a bona ﬁde cell surface receptor/co-receptor
(with other receptors) for signal transduction across the membrane
[59]. However, the complexity of LRP-1 signal transduction mainly
comes from its large ligand binding repertoire. Besides gp96 and
eHsp90, other extracellular heat shock proteins that also bind LRP-1
include calreticulin, eHsp60 and eHsp70 [63–66]. In addition, opposite
roles for LRP-1 signaling have been reported. For instance, LRP-1 has been
shown to play a critical role in PDGF-BB-stimulated ERK1/2 activation and
cell proliferation and also in TGFβ-stimulated anti-proliferation [67,68].
Cheng et al. reported that, while eHsp90α dramatically increased cell mi-
gration, human recombinant Hsp70, gp96 and calreticulin exhibited ei-
ther a modest or no stimulation of cell migration [11]. There is a clear
need to identify the speciﬁc binding site in LRP-1 for eHsp90α, in order
to understand its mechanism of action.
9. Is eHsp90 a design of Mother Nature?
Whenever the extracellular conditions become less than normal,
such as heat shock, the cells down-regulate overall protein synthesis
and yet selectively up-regulate Hsp expressions. This selective in-
crease in chaperones has long been interpreted as helping deal with
protein folding and stability. In fact, there has been little evidence to
support this long-standing claim. Csermely and colleagues argued
that evolution would not have tolerated such an abundant storage
of Hsp90 in the cells, if the function of Hsp90 had had only been an
intracellular chaperone [13]. Therefore, many suspected that those
“extra” Hsp90 serve the similar role as cytoskeletal proteins. Based
on recent studies on eHsp90, the $64,000 question is whether Mother
Nature purposely designed the increase in an already high level of in-
tracellular Hsp90 to supply the “eHsp90 pool” for the cells to deal
with environmental stress. Currently, there has been limited knowl-
edge for or against this previously unthinkable possibility, either.
The answer to the above question for sure will not come in the near
future.
If we jump one step forward to assume the “eHsp90 hypothesis” is
correct, why hadMother Nature chosen Hsp90 (instead of the numer-
ous known cell migration-promoting factors) for this job? What
unique qualiﬁcations was eHsp90 given by Mother Nature and those
qualiﬁcations are absent from those conventional pro-motility fac-
tors, such as growth factors. A possible answer to these questions
merged from a surprising ﬁnding of our group a few years ago. It is
known for long that TGFβ family cytokines block conventional
growth factor-stimulated proliferation in many cell types and migra-
tion in certain cell types. For instance, Bandyopadhay et al. found that











Fig. 3. eHsp90α-driven, not growth factor-driven, cell migration overrides TGFβ inhibition. (Upp
signal of TGFβ, which is abundantly present inwounded tissues or at tumor site. Unlessmutation
on the cells in vivo. (Lower part) eHsp90 is the ﬁrst ligand-like peptide that is able to continue pr
studied. This ﬁnding explains 1) why eHsp90 is more effective than growth factors in skin wounendothelial cell, but not human keratinocyte, migration [69]. This in-
hibition by TGFβ3 was believed to be a major reason for why conven-
tional growth factor therapy in wound healing has largely failed [12].
However, our laboratory found that TGFβ3 was unable to inhibit
eHsp90α-induced migration of any type of human skin cells [11]. This
unique property of eHsp90α is schematically represented in Fig. 3.
Such a superior effect of eHsp90α over growth factors was also reﬂected
in in vivo wound healing studies. Topical application of recombinant
Hsp90α proteins to diabetic mouse wounds dramatically shortened
the time of wound closure from 35 days to ~18 days, signiﬁcantly stron-
ger than becaplermin gel (PDGF-BB) treatment [12]. These authors pro-
posed that it is eHsp90α, but not the conventional wisdom of growth
factors (such as PDGF-BB), that drives inward migration of the dermal
cells into the wound against the TGFβ inhibition. As previously empha-
sized, moving into the wound by these dermal cells is essential for the
wound remodeling and new blood vessel formation.
Similarly, cancer has also a love-and-hate relationship with
TGFβ, which is regarded as both tumor suppressor and tumor pro-
moter [70]. Hanahan and Weinberg in their most cited review of
2000 organized the traits of cancer into six distinct yet overlapping
events; 1) self-sufﬁciency in growth signals; 2) insensitivity to
anti-growth signals; 3) tissue invasion and metastasis; 4) unlimit-
ed proliferative potential; 5) sustained angiogenesis; and 6) pre-
venting apoptosis [71]. They cited that one of the most recognized
anti-growth signals is TGFβ. TGFβ prevents an inactivating phosphor-
ylation of the tumor suppressor gene product Rb in cells, thereby block-
ing the cell's advance through the G1 phase of the cell cycle. In this case,
TGFβ induces increased gene expression of p15INK4B and p21, which in
turn inhibit cyclin:CDK complex's kinase activity responsible for the
inactivating phosphorylation of Rb. In certain cell types, TGFβ also sup-
presses expression of the c-myc proto-oncogene, a positive regulator of
the cell cycle progression. These inhibitory capabilities of TGFβ are obvi-
ously bad news for cancer cells [70]. To sabotage the tumor suppressing
effect of TGFβ, a number of tumors choose to mutate either the type II
(TβRII) or type I (TβRI) TGFβ receptor. Whereas other tumors choose
to eliminate downstream signalingmolecule, Smad4,which forms com-
plexwith activated Smad2/3 to regulate gene expression in the nucleus.
These TGFβ pathway-mutated tumors include gastrointestinal and co-
lorectal cancer [72], gastric ovarian cancer [73,74], breast cancer [72]
and pancreative cancer [75,76]. Those alterations in TGFβ signaling
pathway have presumably made the cancer cells no longer sensitive
to the anti-proliferation and anti-migration signals of TGFβ. However,
in many other human cancers, no mutations in TGFβ signaling compo-
nents are found. How could these cancers bypass the TGFβ's inhibitory
signals? There have been little studies that address this question. If we
put the importance of HIF-1 in cancer and the recent ﬁnding of the







er part) Conventional growth factor-induced cell migration is sensitive to the anti-motility
s take place along the TGFβ signaling pathway, growth factorswill not be able to be effective
omoting cell migration in the presence of TGF-beta. Themechanism of action remains to be
d healing and 2) cancers without mutation in TGFβ signaling pathway progress.
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the following facts: 1) Approximately 40% of all human tumors has con-
stitutively elevated expressionofHIF-1α, the critical subunit of themaster
transcription factor for tissue oxygen homeostasis [41]; 2) HIF-1α is a
central controller of Hsp90α secretion [10,39]; and 3) eHsp90α is re-
quired for cancer cell invasion in vitro [30] and tumor formation in vivo
[32,45,54]. Therefore, it is conceivable that secretion ofHsp90α is an alter-
native strategy for cancer cells to bypass the anti-motility of TGFβwithout
mutating TGFβ signaling components.
10. How was eHsp90 connected to wound healing?
What is the natural driving force of skin wound healing? For de-
cades, the conventional wisdom has been that cell type-speciﬁc
growth factors represent Mother Nature's design for repairing
wounds [2,3]. These growth factors often appear only when skin
is wounded or their concentrations rise signiﬁcantly from a basal
level in response to injury, such as TGFα and KGF (FGF7) for kera-
tinocytes, PDGF-BB for dermal ﬁbroblasts and VEGF-A for dermal
microvascular endothelial cells. Based on this belief, more than 30
growth factors have been subjected to extensive pre-clinical stud-
ies and/or clinical trials alone or in combinations [4]. Despite
these enormous efforts, the in vivo functions for many of these
growth factors remained unconﬁrmed and their efﬁcacy in human
trials mostly fell short of providing signiﬁcant clinical beneﬁts.
Among them all, only recombinant PDGF-BB received the FDA ap-
proval (becaplermin gel) for treatment of diabetic ulcers, as previ-
ously mentioned. Subsequent studies found becaplermin gel low
efﬁcacy and higher risks of causing cancer in patients, resulting in its de-
clined use in clinical practice (http://www.medicalnewstoday.com/
releases/110442.php). This signiﬁcant side-effect may not be surprising
to cancer researchers, since it was already known years before the FDA
approval of becaplermin gel that overexpression of PDGF-BB (c-sis) or
autocrine of its viral form, v-sis, will cause cell transformation and that
yet the recommended dosage of PDGF-BB in becaplermin gel is more
than 1000 fold higher than the range of the physiological PDGF-BB levels
in human circulation. The reason for this stern reality has never been in-
vestigated, even though it challenges whether continued emphasis on
growth factors is the right thing to do for wound healing.
In 2006, Badyopadhay and colleagues made a surprising observa-
tion that had ultimately led to the discovery of an unconventional
wound-healing factor, the eHsp90α. Having noticed that fetal bovine
serum (FBS) has been used to culture human cells for years, the re-
searchers argued that human cells are never in contact with FBS in re-
ality and, instead, it is the human serum that represents the main
soluble environment in wounded skin. They compared the effect of
FBS versus human serum on migration of three major human skin
cell types, epidermal keratinocytes and dermal ﬁbroblasts and micro-
vascular endothelial cells. They found that FBS non-discriminatively
stimulated migration of all three types of human skin cells, as
expected. However, they were surprised to ﬁnd that human serum only
promoted keratinocyte migration, whereas halted migration of the two
dermal cell types. They further revealed that the blocking signal in
human serum comes fromTGFβ3 (not TGFβ1 or TGFβ2) and the selective
sensitivity of the human dermal cells to TGFβ3 is due to their 7–15 fold
higher levels of TβIIR than that in epidermal keratinocytes [69]. An impor-
tant message of this ﬁnding was that conventional growth factors may
not be able to induce proliferation and migration of dermal ﬁbroblasts
and microvascular endothelial cells in vivo, as they do in vitro, due to
abundant presence of TGFβ3 in human serum. These authors speculated
that this defect in growth factors represents a reason forwhy themajority
of the growth factor trials in the past failed to show any promising
efﬁcacy.
If it were not the action of growth factors, what would be the
factor that drives dermal cell migration against TGFβ3 inhibition
in the wound and where would it come from? The researchersreasoned that this critical factor does not come from human
serum, because the latter inhibits dermal cell migration. Instead,
they suggested that it comes from secretion of the migrating keratino-
cytes in response to injury-generated stress signals, such as hypoxia,
and factors that promote keratinocyte migration, such as TGFα [77,78].
More importantly, they proposed that this factor must satisfy the follow-
ing two criteria: 1) being a common pro-motility factor for all three types
of human skin cells and 2) being able to override TGFβ3 inhibition. First,
they detected a strong pro-motility activity in serum-free conditioned
medium of TGFα-stimulated keratinocytes and hypoxia-treated dermal
ﬁbroblasts, which drives migration of all three types of human skin
cells. In subsequent 18 months, from 10 L of serum-free conditionedme-
diumof primary human keratinocytes, protein puriﬁcation allowed them
to discover eHsp90α responsible for the entire pro-motility activity in the
conditioned medium [10,11]. That was a total surprise to these
researchers.
11. eHsp90 carries three unique properties, absent from
conventional growth factors, to effectively heal acute and
diabetic wounds
In vivo, topical application of recombinant Hsp90α proteins short-
ened the time of 1 cm×1 cm full thickness acute wound closure
from more than 2 weeks to ~10 days in nude mice and of similar
wound in db/db (diabetic) mice closure from 35 days to ~15 days
[10,12]. In comparison, becaplermin gel treatment showed little im-
provement on acute (normal) wound healing and only shortened
the time for diabetic wound closure from 35 days to ~28 days.
What has made eHsp90α superior to the conventional growth factor
therapy? Cheng et al. provided three unique properties of eHsp90α.
First, eHsp90 is a common pro-motility factor for all three types of
human skin cells involved in wound healing. Following skin injury,
the lateral migration of keratinocytes closes wound and subsequent
inward migration of dermal ﬁbroblasts and dermal microvascular
endothelial cells into the wound remodels the damaged tissue and
builds new blood vessels. Therefore, ideally, a single factor-based
wound-healing agent should be a molecule that is capable of recruit-
ing all the three types of human skin cells into the wound bed.
eHsp90 is a common pro-motility factor for all the three major
types of human skin cells, because all of the cells express a compatible
level of LRP-1 [11,12]. In contrast, if an agent, such as a growth factor,
that selectively acts on some, but not all, the cell types, it would be less
effective in the multi-cell-type participated process of wound healing.
For instance, PDGF-BB only acts on dermal ﬁbroblasts, but not kerati-
nocytes and dermal microvascular endothelial cells, due to a complete
lack of both PDGFRα and PDGFRβ on the latter two types of cells. Only
human dermal ﬁbroblasts express the PDGFRs. If one extrapolates
these in vitro ﬁndings to equivalent wound healing events, it suggests
that PDGF-BB cannot have a direct role in recruitment of keratinocyte
for wound re-epithelialization and dermal microvascular endothelial
cells for wound neovascularization.
Second, in addition to its selected cell type target, PDGF-BB is un-
able to override inhibition of TGFβ3, which is co-present in the
wound, to promote migration of dermal ﬁbroblasts. This defect cre-
ates an additional hurdle for PDGF-BB to overcome when it is added
to the wound as a therapeutic. In contrast, even in the presence
of TGFβ3, eHsp90α remains equally effective to promote migration
of all three types of human skin cells. The mechanism by which
eHsp90α is able to do so remains to be studied. Third, it is known that
all forms of diabetes are characterized by chronic hyperglycemia in circu-
lation, which is blamed as one of the possibly many factors that delay the
healing of diabetic wounds [79]. A reported damage by hyperglycemia
was to destabilize HIF-1α (hypoxia-inducible factor-1alpha) protein, the
key regulator of Hsp90α secretion, in the wound [80,81]. Cheng et al. re-
cently found that hyperglycemia blocked hypoxia and serum-stimulated
human dermal ﬁbroblastmigration. However, eHsp90 not only enhanced
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cued” migration of the cells cultured under hyperglycemia [12]. We be-
lieve that the eHsp90 promotes diabetic wound healing by
bypassing the hyperglycemia-caused HIF-1α down-regulation and
jumpstarting migration of the cells that otherwise cannot respond
to the environmental hypoxia. Based on these ﬁndings, we propose
a new wound-healing paradigm, as schematically shown in Fig. 4,
to explain what (factor) drives epidermal and dermal cells to mi-
grate into the wound, leading to wound closure. Prior to injury,
eHsp90α, TGFβ3 or cell motility remain minimal in intact skin
(Step 1). Within hours following injury, keratinocytes start to migrate
laterally across the wound (possibly induced by acute hypoxia or
TGFα from serum). At the same time, however, dermal ﬁbroblasts and
dermal macrovascular endothelial cells at the wound edge cannot im-
mediately move into the wound bed due to the presence of TGFβ3 in
serum (Step 2). Migrating keratinocytes start secreting Hsp90α and
once the eHsp90α reaches the threshold concentration of 100 nM
[35], the dermal cells migrate inwardly into the wound bed from the
surroundingwound edge even in the presence of TGFβ3 (Step 3). Final-
ly, the migrating keratinocytes completely close the wound and the
newly moved-in dermal ﬁbroblasts cells start to remodel the wounded
tissue and dermal microvascular endothelial cells to re-build new
blood vessels (Step 4). The dermal neovascularization and remodeling
processes would take many months to complete. Thus, migrating kera-
tinocyte-secreted eHsp90α, instead of conventional growth factorsFig. 4. Amodel of howeHsp90 promotes re-epithelialization and recruits dermal cells into thew
migration or stress; (Step 1) Injury triggers release of TGFβ from several sources, the immotile t
growth factorswill not be able to recruit the dermal cells at thewound edge to thewound bed du
Hsp90α.Whence the secretedHsp90α reaches the threshold concentration ofN0.1 μM, itwill dr
and the moved-in HDFs will start to remodel the wound and HDMECS to build new blood vess
microvascular endothelial cells.
Taken with permission from Ref. [12]).from serum, may be the bona ﬁde recruiting factor of the dermal cells
into the wound.
Finally, the unique property of eHsp90α being a motogen, but not
a mitogen (i.e. it does not stimulate cell proliferation) [10] also makes
physiological sense. First, keratinocyte migration occurs almost im-
mediately following skin injury, whereas the inward migration of
dermal cells is not detected until 4 days later [2]. Second, it is
known that when a cell is migrating, it cannot proliferate at the
same time. Beside, any attempt by on-site growth factors to stimulate
proliferation of both epidermal and dermal cells would be inhibited
by TGFβ that appears whence skin is wounded [12,69]. Third, cell mi-
gration preceeds cell proliferation during wound healing. Then, when
and where does cell proliferation take place in the wounded skin?
Based on the above three facts, we believe that, while the cells at
the wound edge are moving toward the wound bed, they left
“empty space” between themselves and the cells behind them. The
cells behind the migrating cells start to proliferate after losing contact
inhibition with the front moving cells. The stimuli of the cell prolifer-
ation likely come from plasma growth factors diffused from sur-
rounding unwounded blood vessels, where TGFβ levels are low or
undetectable. Thus, the role of cell proliferation in wound healing is
to re-ﬁll the space generated by the front-migrating cells. The speciﬁc
role of eHsp90α is to help to achieve the initial wound closure as quick-
ly as possible to prevent infection,water loss, and severe environmental
stress. Many other factors (including growth factors and TGFβ) mustoundduringwoundhealing. (Step 0)Uninjured intact skinwith little detectable TGFβ, cell
omotile transition of keratinocytes and release conventional growth factors. However, the
e to thepresenceof TGFβ; (Step 2)while keratinocytes aremigrating, they release/secrete
ive inwardmigration ofHDFs andHDMECs; (Step 3) TheHKs are about to close thewound
els. HK, human keratinocyte, HDF, human dermal ﬁbroblast and HDMECs, human dermal
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cesses (up to 12 months).
12. How was eHsp90 connected to cancer and to what types
of cancer?
Although eHsp90 was reported as a cell surface-bound tumor anti-
gen back in 1970s, the ﬁrst direct evidence for eHsp90 in tumor cell in-
vasion in vitro and tumor formation in nude mice came from two
relatively recent studies. Both of these studies used membrane imper-
meable 17-AAG inhibitors to block the action of eHsp90 and reported
for the ﬁrst time requirement of eHsp90 for tumor progression
[42,45]. Stellas et al. used a mAb, 4C5, against Hsp90α to conﬁrm the
importance of eHsp90 in breast cancer cell “deposits” in nude mice
[54]. Sahu and colleagues found that permanent down-regulation of
the LRP-1 receptor inMDA-MB-231 cells dramatically reduced lung col-
onization of the cells in nude mice [42]. However, all these studies suf-
fered from technical limitations that should have made the
investigators refrain from making any deﬁnitive conclusions, like those
they had had made. First, DMAG-N-oxide treated melanoma cells were
reported to have decreased lung colonization in vivo [45]. However, it is
hard to understand how a single pre-treatment of the cells with the
drug in vitro could have had the reported long lasting effect after the
cells were injected intomice. Second, Patsavoudi and colleagues reported
that mixing breast cancer cells with 4C5 in vitro prior to injection into
nudemice resulted in reduced lung deposits of the cells within hours fol-
lowing injection [54]. Under these conditions, there would have been no
way to knowwhether the co-injected 4C5 could have worked by contin-
uously binding and neutralizing constantly secreted Hsp90α and Hsp90β
by the tumor cells for the entire period of the experiments. It wouldmake
more sense to inject and maintain a steady-state amount of DMAG-N-
oxide or 4C5 in circulation, prior to injection with the tumor cells. For
DMAG-N-oxide, stability in the animals was cited as the reason for ex-
cluding injection into blood. Third, while the data was convincing that
breast cancer cells lacking the LRP-1 receptor were unable to effectively
form tumors in nude mice, the effect of down-regulation of LRP-1 may
not necessarily be due to speciﬁc blockade of eHsp90α signaling. LRP-1
is known to bind a number of other ligands [82]. Thus, to prove the essen-
tial role of eHsp90, there is a need to developmore speciﬁc and stable in-
hibitors against the pro-motility function of eHsp90.
Nonetheless, it has come to the clinically important question if tumors
do or do not secrete Hsp90. So far, at least one critical regulator of Hsp90
secretion has been established. Li et al. showed that HIF-1α mediates
hypoxia-induced Hsp90α secretion in human dermal ﬁbroblasts and
keratinocytes. Forced expression of a constitutively activated HIF-1α,
CA-HIF-1α, was sufﬁcient to replace hypoxia to cause HIF-1α secretion
[10,39]. This ﬁnding is relevant to cancer, since HIF-1α overexpression
is associated with increased patient mortality in approximately 40% of
human solid tumors, independent of other speciﬁc mechanisms [41].
Taking breast cancer as an example, Dales et al. carried out anti-HIF-
1α immunohistochemical assays on frozen sections of 745 breast cancer
samples and found that the levels of HIF-1α expression correlated to
poor prognosis, lower overall survival and high metastasis risk among
both node-negative and node-positive patients [83]. By using HIF-1α
expression as a marker, it was estimated that approximately 25–40%
of all invasive breast cancer samples are hypoxic, suggesting that HIF-
1α may be used as a broader marker for breast cancers [82]. Sahu et
al. have recently shown that down-regulation of the endogenous and con-
stitutively expressed HIF-1α in breast cancer cell lines,MDA-MB-231 and
MDA-MB-468, completely blocked Hsp90α secretion, and the secretion
could be rescued by re-introducing RNAi-insensitive WT-HIF-1α and
CA-HIF-1α, but not DN-HIF-1α, genes [32]. These data establish that
HIF-1α is a crucial and direct upstream regulator of Hsp90α secretion. If
we extrapolate these ﬁndings and numbers on HIF-1α and cancer pro-
gression, it suggests that eHsp90α plays an important role at least
in those HIF-1α-overexpressing (≥40%) tumors in humans.13. Is eHsp90 amore effective and less toxic target than intracellular
Hsp90 for treatment of the tumors?
Inmany, but not all, tumor cells, Hsp90 has been found either quan-
titatively overexpressed or qualitatively overactivated (with similar
expressing levels of normal cells) [85]. In either case, these seemingly
“cancer-related” Hsp90 proteins are believed to bind and protect the
stability and, therefore, oncogenecity of the oncogene products [84].
Such higher degrees of protection of the oncoproteins by these Hsp90
proteins in tumor cells than that of cellular proteins in normal cells
are viewed as an opportunity for anti-tumor drugs. Geldanamycin
(GM, or benzoquinone ansamycin) and its derivatives inhibit the ATP-
binding and ATP hydrolysis functions of Hsp90 and have been the
focus of anti-tumor drug development for two decades [86,87]. Many
of the earlier trials did not advance. Several newer generations of chem-
ically modiﬁed and less toxic GM-related drugs are being developed and
tested in a dozen of new clinical trials [88,89]. An obvious key hurdle of
these trials is how to minimize their potential interference with the
physiological chaperone function of Hsp90 in surrounding normal tissue
and cells and selectively harm the “cancer-related” Hsp90 proteins in
tumor cells embedded next to the normal cells. It has proven difﬁcult
for Hsp90 inhibitors of this nature [89].
In contrast, no physiological function has been reported for the ac-
tion of eHsp90, which requires the F-5 epitope within the highly
charged linker region and part of the middle domain in Hsp90α.
Using gene rescue experiments, Picard and colleagues showed that a
highly charged linker region in yeast Hsp90 (Hsp82), which overlaps
with the F-5 epitope of human Hsp90α, was dispensable for viability
in yeast [90]. This genetic datum, together with all the studies for the
past 7 years, suggests that secretion of Hsp90 by normal cells is an
emergency response of the cells to environmental insults, such as nor-
mal cells in a wounded tissue or cancer cells in a hypoxic environment.
Furthermore, eHsp90 does not require the ATPase region, which is the
target for the GM-related inhibitors and the reason for the drug-caused
cytotoxicity. Therefore, the F-5 epitope in eHsp90αmay represent an ex-
cellent target for design of safer, effective andmore speciﬁc inhibitors for
treatment of HIF-1α-positive tumors. Therefore, we propose that new
anti-cancer drugs should i) selectively inhibit eHsp90 (not its intracellular
counterpart) and ii) speciﬁcally target at the pro-motility activity located
at the F-5 region. Drugs that bear both properties should achieve a higher
efﬁcacy and pose minimum toxicity to cancer patients. A schematic rep-
resentation of this simpliﬁed thought is depicted in Fig. 5.
14. Wound healing and tumor progression: similar strategy used
by peacemaker and terror
What is the relationship between wound healing and cancer?
Wound healing is a physiological repair process by epithelial, ﬁbroblastic
and endothelial cells that is only activated in response to injury or a sur-
geon's knife. Cancer is inmanyways a similar process by a similar group
of cells (called tumor stroma cells as a distinction) in response to the
“injury” that is caused by the invading tumor cells.Wound healing usu-
ally has a beginning and an ending, whereas cancer has a beginning but
often an open ending (patient death) if left untreated. In his seminar-
converted analytical article published in The New England Journal of
Medicine, Dvotak listed lines of similarities (and distinctions) between
wound healing and tumor stroma generation and suggested that tumor
stroma formation is a subversion of the normal wound healing process.
Therefore, he called tumors “wounds that do not heal” [91].
Such a reverse relationship of “healing” and “no healing” between
wound healing and cancer should be taken into account, whence
eHsp90 becomes a clinical target. For instance, topical application of
F-5 peptide to wounds has to consider if the peptide goes into the
blood circulation and travels to the site where an early-stage tumor
is in progress. Under this circumstance, F-5 might aid the tumor cell
invasion and speed up its growth. On the other hand, administration
eHsp90α














Fig. 5. A model of secreted Hsp90α as a potential target for HIF-1α-positive cancers. The
severe hypoxia often found at the center of a stroma-surrounded tumor. Gene mutations
in the tumor cells have caused constitutive accumulation of HIF-1α, even under normoxia.
The deregulated HIF-1α triggers secretion of Hsp90α via exosomal protein trafﬁcking
pathway. The secretedHsp90α binds, via F-5 epitope, to cell surface LRP-1 receptor and pro-
motesmotility and invasion of tumor cells in an autocrine fashion.While current clinical trials
focus on intracellular Hsp90α, we propose that drugs that target the F-5 region of secreted
Hsp90α are more effective and safer in treatment of cancer patients.
Modiﬁed with permission from Ref. [32].
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growth might interfere with the normal wound healing process in
the same patient. This is a legitimate and realistic concern. For example,
numerous studies showed that the peoplewith type II diabetes aremore
likely to die from cancer than non-diabetic people. Therefore, for a dia-
betic patient who has cancer and a foot ulcer, if the patient is treated
with inhibitors of F-5 by an oncologist to slow the cancer progression,
the administered inhibitor could interfere with the healing process of
the chronic wound managed by a wound specialist. The reverse is true.
If the diabetic ulcer is treated with F-5 peptide, the peptide may travel
through the blood circulation to the tumor site and to aid invasion and
metastasis of the tumor. It is important to knowwhat patients should re-
ceive the treatments and what patients should not.
15. Conclusion and perspective
It is becoming clear that Hsp90 has two Mother Nature-signed roles
to play. One is as an intracellular chaperone and the other is as an extra-
cellular tissue-repairing factor, both ofwhich seem to be designed for the
cells to cope with environmental changes, such as tissue injury. Both
functions have been taken advantage of by tumor cells during invasion
and metastasis. A central controller of Hsp90 secretion inside the cells
is HIF-1α, which is overexpressed in more than 40% solid tumors in
humans. LRP-1 is essential for eHsp90 signaling topromote cellmigration
and tumor invasion.More importantly, the recognition of eHsp90's exis-
tence and its role in tissue repair and cancer invasion has revealed a
new line of therapeutic intervention. Evidence-based advantages of tar-
geting eHsp90 over conventional growth factors for wound healing
have been shown in pre-clinical studies. Predicted advantages of target-
ing eHsp90 over intracellular Hsp90 in prevention of tumor progression
remain to be tested, upon availability of speciﬁc inhibitors. A crucial tool
for the future studies is to develop inhibitors that speciﬁcally target the
F-5 region of eHsp90 for both in vitro and in vivo experiments. Mean-
while, for the next 5 years, important questions such as mechanisms
of Hsp90 secretion and eHsp90 actionwill continue keeping researchers
busy and challenged.
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